Non applicability of Regulation 32(1) of SEBI (LODR) Regulation, 2015 for the year ended 31st March, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Ishita Drugs & Industries has filed a routine compliance update with BSE confirming that Regulation 32(1) of the SEBI Listing Obligations and Disclosure Requirements (LODR) Regulations, 2015 does not apply to the company for the financial year ended 31 March 2025. This regulation normally requires listed companies to submit a Statement of Deviation or Variation when they raise money through a public issue, rights issue, preferential issue, or qualified institutions placement (QIP). The company has confirmed it did not raise any funds through any of these routes during FY25. As a result, no deviation or variation statement is required to be filed. The intimation has been signed by Managing Director Jagdish Prasad Agrawal.
This is a routine, non-material compliance disclosure with no direct impact on shareholders or the stock price. Investors should note that Ishita Drugs did not undertake any equity fund-raising activity through public, rights, preferential, or QIP routes in FY25.